LIPAC Oncology, LLC

AN2 Therapeutics, Inc., based in Atherton, CA, is dedicated to developing novel therapies through its innovative boron chemistry platform. The company's experienced leaders are committed to enhancing global human health by delivering first-in-class drug discovery approaches targeting infectious diseases and oncology. With a promising pipeline of boron-based compounds, AN2 Therapeutics aims to create best-in-class therapeutics, including their investigational drugs for conditions such as Chagas disease and melioidosis. Their mission reflects a passion for scientific advancement and an unwavering focus on improving patient outcomes. Generated from the website

Jazz Pharmaceuticals is a specialty pharmaceutical company that specializes in the development and commercialization of neurological and psychiatric products. The company offers products of various brands that include Xyrem and Antizol. Its products are used as an antidote for ethylene glycol and methanol ingestion. Jazz Pharmaceuticals offers support and guidance on reimbursement to patients through its patient affairs area and is a provider of chronic, patient-administered products. The company provides patient assistance programs on Xyrem and Cystadane through the National Organization of Rare Disorders, a nonprofit organization that specializes in the identification, treatment and cure of orphan diseases. Jazz Pharmaceuticals is headquartered in Palo Alto, Calif.

Kalaris Therapeutics, Inc. is a clinical-stage biopharmaceutical company based in Palo Alto, California, focused on developing innovative treatments for prevalent retinal diseases. Founded by experienced leaders in ophthalmology, the company aims to address significant unmet needs by creating therapies that ease the burden on patients and caregivers while improving treatment outcomes. The company's lead product, TH103, is a fully humanized recombinant fusion protein designed for intravitreal delivery, demonstrating potential as a best-in-class anti-VEGF agent. With an experienced management team and support from veteran investors, Kalaris is currently evaluating TH103 in a Phase 1 clinical trial for neovascular age-related macular degeneration, with plans to expand its application to other neovascular and exudative retinal diseases. Generated from the website